$0.14
-0.02 (-10.71%)
Open$0.15
Previous Close$0.16
Day High$0.16
Day Low$0.12
52W High$0.90
52W Low$0.08
Volume—
Avg Volume277.3K
Market Cap5.09M
P/E Ratio—
EPS$-0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,585.7% upside
Current
$0.14
$0.14
Target
$3.76
$3.76
$2.62
$3.76 avg
$5.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.23M | 7.84M | 7.68M |
| Net Income | -32,433,406 | -2,005,672 | -1,738,578 |
| Profit Margin | -619.8% | -25.6% | -22.6% |
| EBITDA | -33,006,236 | -2,263,216 | -2,551,790 |
| Free Cash Flow | — | -1,406,564 | -1,071,377 |
| Rev Growth | — | +12.8% | +0.1% |
| Debt/Equity | 0.06 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |